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A comparison of the responses to recombinant human erythropoietin in
normal and uremic subjects. The erythropoietic response to graded
doses of recombinant human erythropoietin (epoetin alfa) was assessed
in 24 hemodialysis patients by quantitative ferrokinetic studies, and
measurement of the reticulocyte count and plasma levels of transferrin
receptor protein. These responses were compared to those of 22 normal
subjects. Epoetin alfa was given intravenously at 15, 50 or 150 U/kg
every other day for four injections. Three patients with chronic renal
failure were restudied after renal function was restored following renal
transplantation. The results of these three different measurements of
erythroid function showed that the acute response to recombinant
human erythropoietin was similar in normal subjects and patients with
renal failure. We conclude that chronic uremia does not alter the
responsiveness to erythropoietin in vivo.
The normochromic, normocytic anemia associated with
chronic renal failure (CRF) has been considered multifactorial,
with relative erythropoietin (Epo) deficiency and erythroid
inhibition by uremia considered the major causes [1]. Shorten-
ing in red cell life span and bleeding secondary to platelet
dysfunction may also contribute to the anemia [2]. Epo defi-
ciency was assumed to be a major cause ever since Jacobson et
a! determined that the kidney was the primary source of Epo
production [3], and plasma levels of Epo in patients with CRF
(as determined by a biological assay in exhypoxic rats) were
inappropriately low for the degree of anemia [4, 5]. Studies,
both in vitro [6—9] and in vivo [10, 11], however, suggested that
uremic inhibitors may decrease erythropoiesis. If such inhibi-
tors existed, Epo might be relatively ineffective as a therapeu-
tic.
To address the question as to whether uremia blunts the
effectiveness of Epo, we established an animal model of stable
renal failure with anemia in the sheep [12] and studied the effect
of Epo-rich sheep plasma in normal animals and then in the
same animals after they had been made uremic. We concluded
that there was no inhibition of the effectiveness of Epo by
uremia in that model [13]. Since then, recombinant human Epo
(epoetin) has become available as a therapeutic and has been
demonstrated to be highly effective in patients with CRF,
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including those on dialysis [14—20] and those with progressive
renal insufficiency [21—25]. However, the individual responses
to epoetin in patients with CRF are variable, and a wide range
of maintenance therapeutic doses are required [19, 26]. It is
important to know whether the response to epoetin therapy is
blunted in uremia, because if it were, strategies could be
designed to determine whether the factors responsible could be
reversed, thereby reducing dosage and cost.
In this study, we have compared the response to epoetin
administration in normal subjects with the response in patients
on dialysis. We assessed erythropoiesis by quantitative ferroki-
netics, reticulocyte counts (corrected for the hematocrit) and
plasma levels of transferrin receptor protein (TRP) before and
after four injections of graded doses of epoetin. Using this
standardized protocol, we found no evidence that uremia
inhibited the acute erythroid marrow response to Epo.
Methods
Subjects
Twenty-four hemodialysis patients were part of the clinical
trials in the United States with epoetin alfa [15, 19]. Two of
these patients subsequently received a kidney transplant and
were restudied when renal and marrow function were normal.
Another patient with progressive renal failure was part of a
clinical study with epoetin [23], and later was restudied when
hematologically normal after receiving a kidney transplant.
Sixteen normal subjects served as controls. Six additional
subjects had hemochromatosis and had been undergoing peri-
odic therapeutic phlebotomy. They were selected for study in
order to provide control subjects with excessive iron stores,
similar to the iron excess present in some of the CRF patients.
The hemochromatosis patients were studied no less than two
weeks after a 200 ml phlebotomy. Adequate iron availability for
our subjects was defined as a baseline serum ferritin greater
than 25 nglml and a percent transferrin saturation greater than
20. The dialysis subjects, as participants in clinical trials, did
not have evidence of osteitis fibrosa, severe aluminum excess,
marked hemolysis or folate depletion [15, 19]. The study was
approved by the Institutional Review Board of the University of
Washington and signed consent was obtained from all partici-
pants.
Study protocol
Baseline studies included: hematocnt, serum creatinine, Se-
rum iron, total iron binding capacity (TIBC), serum ferritin (all
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measured by routine laboratory methods); serum Epo (radio-
immunoassay [27]), reticulocyte count (corrected for the hem-
atocrit), ferrokinetics (plasma iron turnover [28] and erythron
transferrin uptake [29]) and plasma levels of TRP [30]. Ferroki-
netics were performed by injecting 2.0 pCi of 59Fe as ferrous
sulfate, followed seven days later by the injection of 5.0 pCi of
59Fe. The erythron transferrin uptake (ETU) was derived from
the plasma iron turnover, and corrected for non-erythroid iron
fluxes and the degree of transferrin saturation [29]. Plasma TRP
levels were measured by an enzyme-linked immunosorbant
assay [30]. The erythropoietic stimulation test was performed
as follows: epoetin alfa (either 15, 50 or 150 U/kg) was given
intravenously every other day for four doses, and the baseline
studies were repeated 24 hours after the fourth dose of epoetin
except for serum Epo and creatinine levels. Serum creatinine
levels were obtained prior to dialysis for the hemodialysis
patients, and at baseline for the other subjects.
Epoetin alfa was provided as Epogen® by AMGEN, Thou-
sand Oaks, California, USA.
Statistical analysis
The two-sample f-test for unequal variances was used to test
for differences between the mean parameter values of normal
and uremic subjects [31]. The correlation coefficients of the
linear relationships were computer-derived.
Results
The mean (± SD) baseline pre-dialysis creatinine for the 24
anemic hemodialysis patients study was 12.4 2.8 mgldl which
was associated with a baseline hematocrit of 20.4 2.9, and a
serum Epo level of 19.3 9.6 mU/mi (N = 23). Four patients
received 15 U of epoetin per kg, five patients received 50 U/kg
and 15 received 150 U/kg.
The 22 normal controls had a mean baseline hematocrit of
42.1 3.8, and a baseline serum Epo of 21.3 5.1 mU/mi (N
21). Their serum creatinine was 1.0 0.1 (N = 20) mg/dl. Six
subjects received 15 U of epoetin per kg, five subjects received
50 U/kg and 11 subjects received 150 U/kg. One subject
receiving 50 U/kg and five subjects receiving 150 U/kg had iron
excess due to primary hemochromatosis.
Red cell production, as quantitated by the ETU, corrected
reticulocyte count and TRP, increased significantly after four
doses of epoetin both in hemodialysis patients and those with
normal renal function (Tables 1 and 2, Figs. 1 to 3). In general,
there was a dose-response relationship for all three measures of
erythropoiesis. The erythropoietic response was similar in both
the hemodialysis and subjects with normal renal function.
However, the hemochromatosis subjects, when compared to
the other normal subjects, had an exaggerated increase in ETU
(P < 0.001), but not in reticulocytes and TRP, when epoetin
was given at a dose of 150 U/kg every other day for four doses
(Fig. 1, Table 1).
There was a good correlation between the ETU and plasma
TRP levels for all study subjects, except those with hemochro-
matosis, before and after four doses of epoetin. The correlation
coefficients for these pre- and post-epoetin observations were r
= 0.66, P < 0.001, (N = 40), and r = 0.38, P < 0.02, (N = 40),
respectively.
The percent increase in ETU, corrected reticulocyte count
and plasma TRP levels were determined after four doses of
epoetin for all study subjects (data not shown). The percent
increase in erythropoiesis following acute epoetin therapy at 15,
50 and 150 U/kg, was not greater in the normal subjects or
hemochromatosis patients when compared to the CRF patients.
Erythropoiesis was quantitated in three CRF patients before
and after successful kidney transplantation (Table 3). The
hematocrit varied between 18 and 29 prior to epoetin therapy
for the anemia of CRF, and was 38.6 to 40 after kidney
transplantation. Patient 8216 was anephric on dialysis and
patient 1702 had not yet required dialysis. Creatinine values
ranged from 9.8 to 17.9 mg/dl associated with the anemia of
CRF, and ranged from 1.2 to 1.7 mg/dl after transplantation.
The mean serum Epo levels were similar: 23 mU/mi (CRF)
versus 21 mU/mi (transplant). The erythropoietic response to
the same dose of epoetin was similar, regardless of the level of
renal function (Fig. 4).
Iron deficiency may limit the erythroid response to epoetin.
The CRF patients all had adequate iron stores as assessed by
serum ferritin and transferrin saturation, mainly because of
prior red cell transfusions. Normal subjects often had a tempo-
rary decline in serum ferritin and transferrin saturation after
four injections of epoetin. One week after the last epoetin
injection, these values had returned to baseline (data not
shown). In some subjects, transferrin saturation and serum
ferritin levels decreased to values associated with iron defi-
ciency. Since these subjects had similar erythropoietic re-
sponses as did those subjects with CRF, we concluded that this
transient laboratory evidence of iron deficiency did not quanti-
tatively impair the erythroid response in the groups, and so data
were pooled.
Discussion
The hypoproliferative anemia associated with CRF has con-
tributed to significant morbidity, both in dialysis patients and
those with progressive renal failure [11. This anemia is now
correctable with epoetin therapy [14—25]. However, the etiol-
ogy of this anemia remains controversial. Traditionally, the
anemia has been considered multifactorial, with the major
factors being relative Epo deficiency, uremic inhibitors of
erythropoiesis, shortened red cell survival, and bleeding sec-
ondary to platelet dysfunction. Platelet dysfunction, as mea-
sured by a prolonged bleeding time [32], improves with (but is
not always corrected by) dialysis, and is normalized when the
hematocrit increases to 30 or more, either by red cell transfu-
sions or epoetin therapy [33—36]. Red cell survival, which
usually doesn't improve with dialysis therapy [1], has improved
in some patients with epoetin therapy [2, 37], suggesting that
anemia, per se, may affect red cell life span. As an indication of
the relatively minor role the hemolysis contributes to the
anemia, a mildly shortened red cell life span doesn't increase
the dose requirements of epoetin in hemodialysis patients [38].
In 1957, the kidney was shown to be the major source of Epo
production [3] and, subsequently, serum Epo levels were
shown to be inappropriately low in CRF, whether measured by
bioassay [4, 5, 39] or radioimmunoassay [40—42]. However,
despite the evidence that renal dysfunction results in inade-
quate Epo production, many investigators believed that solutes
retained in uremia blunted the erythropoietic action of Epo.
Four observations supported this thesis. First, when murine
or canine erythroid cells are cultured in vitro with Epo, the
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Table 1. Response to epoetin in normal subjects
90 1.7 6.8
124 3.1 7.8
73 1.4 6.1
64 1,7 7.6
49 1.8 4.1
51 2.6 4.8
49 1.6 5.0
56 1.6 5.3
61 1.5 2.6
89 2.9 3.9
51 1.8 4.0
67 3.0 4.7
62 1.6 4.8
16 0.1 1.5
75 2.5 5.7
27 0.7 1.6
58 2.1 5.9
80 2.8 8.9
61 0.9 4.7
70 2.1 7.2
27 1.1 6.9
78 2.3 8.2
118 1.9 7.6
174 3.0 8.5
115 3.5 3.2
137 4.4 5.5
76 1.9 5.7
40 1.0 1.8
108 2.9 7.7
46 0.9 1.4
63 1.3 5.8
122 3.2 8.5
92 1.4 5.9
116 2.6 9.7
43 1.4 4.1
86 2.3 8.2
77 1.2 4.9
96 2.1 8.8
84 1.3 4.9
106 4.0 6.6
78 1.5 7.5
105 4.6 10.0
73 1.4 5.5
17 0.1 1.2
105 3.1 8.6
13 1.0 1.2
Hct
Serum
Retic TRPCr Epo Fe TIBC TS Ferr
Subject % mg/dl mU/mi jAg/di jsgldl % ng/ml PIT ETU % /sg/ml
1.1 31 83 283 29 193 0.90
89 259 34 134 1.23
0.9 17 96 287 25 7 0.75
41 259 34 4 0.68
0.9 17 102 312 33 67 0.61
35 280 13 33 0.47
1.2 24 62 357 17 26 0.50
42 345 12 28 0.50
1.2 19 159 310 51 149 0.82
116 290 40 102 0.99
1.0 29 65 244 27 37 0.56
63 222 28 17 0.70
1.1 23 95 299 30 80 0.69
0.1 6 35 38 11 75 0.16
64 276 27 53 0.76
32 41 12 52 0.30
1.1 13 55 366 15 45 0.54
48 347 14 18 0.68
1.2 27 97 316 31 52 0.69
32 279 11 19 0.58
1.0 — 52 275 19 28 0.33
49 303 16 18 0.68
1.1 21 64 279 23 191 1.06
102 284 36 166 1.69
— 16 165 379 44 304 1.31
175 401 44 190 1.51
1.1 19 87 323 26 124 0.79
0.1 6 47 48 11 120 0.40
81 323 24 82 1.03
59 51 15 88 0.53
1,1 27 88 308 29 95 0.68
37 313 12 33 0.94
1.0 17 136 322 42 30 1.04
43 310 14 11 0.93
0.8 22 64 267 24 36 0.49
33 280 12 13 0.70
1.1 24 63 345 18 14 0.71
31 302 10 9 0.74
1.0 19 122 337 36 108 0.93
61 331 18 54 0.91
0.9 17 104 355 29 67 0.83
39 343 11 18 0.82
1.0 21 96 322 30 58 0.78
0.1 4 30 32 9 38 0.20
41 313 13 23 0.84
11 22 3 18 0.10
15 U/kg
8507
8508
8509
8510
8513
8514
Mean
SD
Mean
SD
50 U/kg
8517
8518
8521
8522
8528(h)
Mean
SD
Mean
SD
150 U/kg
8501
8502
8503
8504
8505
8506
Mean
SD
Mean
SD
8523(h)
8524(h)
8525(h)
8526(h)
8530(h)
Mean(h)
SD
Mean(h)
SD
42.2
43.0
45.5
47.0
42.4
45,5
41.0
37.6
44.0
45.0
43.0
1.8
43.6
3.7
0.8 21 140 306
52 305
1.0 29 247 326
158 310
1.0 21 309 350
270 297
— 22 154 370
91 325
0.9 15 190 302
116 329
46 361
17 176
76 602
51 299
88 1973
91 1412
42 299
28 193
63 434
35 331
0.96
1.39
0.87
1.47
1.18
2.45
0.87
1.47
1.26
2.03
80 3.7 6.2
173 7.4 7.4
51 2.2 4.2
130 4.6 5.7
71 2.4 4.3
191 7.0 5.8
69 2.4 4.9
159 4.6 8.8
98 2.8 4.3
214 5.8 7.7
0.9 22 208b 331 63b 734d 1.03
0.1 5 70 29 20 702 0.18
137" 313 44C 482" 1.76a
84 14 29 524 0.46
74
17
173
32
2.7a
0.6
59b
1.3
4.8
0.8
7.1
1.3
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Table 1. Continued
Subject
Hct
%
Serum
PIT ETU
Retic
%
TRP
jsg/ml
Cr
mg/di
Epo
mU/mi
Fe
g/dl
TIBC
pg/dl
TS
%
Ferr
ng/mi
Mean(N=
SD
Mean (N =
SD
11)
11)
41.8
4.0
42.4
4.2
1.0
0.1
21
4
147
76
85
73
326
29
313
18
45
22
27
25
365
568
232
409
0.89
0.22
1.26
0.57
73
16
136
42
2.0
0.8
4.4
1.8
5.2
1.0
7.9
1.5
Abbreviations are: (h), hemochromatosis; Het, hematocrit; Cr, serum creatinine; Epo, serum erythropoietin; Fe, serum iron; TS, transferrin
saturation; TIBC, total iron binding capacity; Ferr, serum femtin; PIT, plasma iron turnover, mg/dl whole blood/day; ETU, erythron transferrin
uptake, mo1 iron/liter whole blood day; Retic, reticulocytes, corrected; and TRP, transferrin receptor protein.
a P < 0.001 differences between mean pre-study valuesb P < 0.01 hemochromatosis vs. normal subjects
v P < 0.05 vs. mean post-study valuesd P < 0.1 hemochromatosis vs. normal subjects
addition of uremic human sera (as opposed to normal sera)
blunts the growth of erythroid colonies (from erythroid colony
forming cells; CFU-E) [6—9]. This in vitro erythroid inhibition is
thought to be due to polyamines [43], such as spermine [9] or
putrescine [44]. Second, Epo-rich plasma from patients with
aplastic anemia, when infused into normal subjects or patients
with varying degrees of CRF, resulted in reticulocytosis in the
normal subjects but not in the severely uremic patients [11].
Third, serum Epo levels, although always inappropriately low
in CRF, occasionally are slightly higher (that is, 30 to 100
mU/ml) than normal [39, 45—47], yet anemia persists, suggesting
that the erythroid marrow is unable to respond to the circulating
Epo in these patients. Finally, some CRF patients, when begun
on hemodialysis [481 or switched to continuous ambulatory
peritoneal dialysis (CAPD) [49], have had a significant increase
in hematocrit without significant increases in serum Epo levels,
suggesting that an inhibitor may have been removed by dialysis.
Other studies have not supported the idea that uremia blunts
the action of Epo. We have shown that the inhibition by uremic
sera of in vitro hematopoiesis is not specific for erythropoiesis:
there is also inhibition of in vitro granulopoiesis and megakary-
opoiesis [50—52]. Thus, the clinical relevance of this in vitro
inhibition of marrow cell growth is unclear, since granulocyte
and platelet production are not suppressed in CRF. Further-
more, uremic inhibition of erythropoiesis is not observed if Epo
is added to cultures of marrow cells from CRF patients along
with autologous sera [53].
The polyamines—spermine, spermidine and putrescine—are
thought to be uremic solutes that might inhibit erythropoiesis,
based upon in vitro studies [9, 44]. However, while these
polyamines may circulate at increased concentrations in CRF,
only putrescine concentrations correlate with the degree of
anemia [54]. Other investigators, using similar analytical meth-
ods, have failed to detect elevated levels of these polyamines in
severe CRF [55]. Finally, the fact that normal hematocnts are
found in as high as 3 to 5% of patients with CRF not receiving
epoetin argues against a universal uremic erythroid toxin [56].
Circulating Epo levels are occasionally higher than normal in
CRF, although the range of serum Epo levels overlaps the
normal range [47, 57]. Serum Epo levels in our patients were
similar to our normal controls (19.3 9.9 vs. 21.3 5.1
mU/ml). The highest level in our CRF patients was 48 mU/mi,
associated with a hematocrit of 18. The patient was anephric
and had minimal erythropoiesis as quantitated by ferrokinetics.
Since the liver can increase Epo mRNA production in the
presence of hypoxia and uremia [58], it is conceivable that the
elevated Epo levels in CRF are of hepatic origin.
Erythropoiesis can be quantitated by ferrokinetics, absolute
reticulocyte numbers and by plasma levels of TRP. Ferrokinet-
ics, in which the ETU is calculated, measures the total produc-
tion of red cells [29]. The number of reticulocytes, when
corrected to a normal hematocrit, reflects effective erythropoie-
sis. Plasma levels of TRP are also a reflection of total erythro-
poiesis [30]. If hemoglobin synthesis increases (as a result of
increased Epo stimulation), or the erythroid marrow requires
more iron (as in iron deficiency), TRP levels increase [30].
Therefore, these three tests quantitate erythropoiesis. Since
plasma levels of TRP correlate with ETU, measurement of
plasma TRP before and after a period of epoetin therapy may
predict the clinical effectiveness of a given epoetin dose.
Our Epo stimulation test was predicated on the protocol and
findings of the first epoetin alfa clinical trial: the hormone was
given intravenously three times a week, and at fixed doses. In
that study, we observed dose-dependent increases in quantita-
tive ferrokinetics and corrected reticulocyte counts [15]. We
also applied that method of evaluating acute responses to
epoetin administration by comparing the findings in patients
with progressive renal insufficiency not yet requiring dialysis
with the findings in dialysis patients [23]. The results indicated
very similar, if not identical, early responses to epoetin in the
two groups.
We have now expanded those earlier observations to com-
pare the acute responses to epoetin in CRF patients and normal
subjects. Using this protocol to monitor changes in erythropoie-
sis, we observed similar increases in ferrokinetics, reticulocytes
and TRP levels in normal and uremic subjects. However, in our
normal subjects, the serum iron, transferrmn saturation and
serum ferritin levels decreased—often to levels compatible with
iron deficiency—especially with the two larger doses of epoetin.
These values returned to baseline one week after discontinua-
tion of epoetin. Since all of the dialysis patients studied had
evidence of adequate or increased iron stores, iron deficiency
was not a limiting factor in their response to epoetin. To ensure
that a transient decrease in serum iron (and transferrmn satura-
tion and serum ferritin) did not modify the response to epoetin
in the normal subjects, we studied six subjects with primary
Table 2. Response to epoetin in chronic renal failure
20.7
16.2
22.4
21.2
20.0
19.2
18.2
17.4
18.0
18.4
22.8
21.6
19.0
18.5
23.5
17.8
19.2
16.6
24.5
26.8
19.6
16.5
17.5
19.6
25.5
27.4
23.0
20.2
17.2
19.2
24.2
24.5
23.4
22.1
17.0
20.6
21.6
25.8
18.5
22.5
15.0
15.6
22.8
24.6
20.2
22.2
16.6
17.5
48 147 289 52 885
77 312 27 —
16 65 229 27 139
62 241 26 —
26 79 352 22 111
59 308 18 —
— 214 244 88 1256
79 217 36 —
11 212 230 94 2061
123 229 51 —
17 113 255 47 508 0.52
8 68 50 29 451 0.11
81 252 33 357 0.95
48 45 21 440 0.31
30 1.1 1.7
56 2.2 1.8
28 1.4 5.1
62 2.7 5.8
46 2.1 3.8
69 2.6 5.8
57 1.2 4.1
113 2.0 6.2
7 0.6 2.52
60 3.1 4.43
24 1.0 3.60
72 1.8 4.26
33 1.0 3.88
66 3,4 4.98
21 0.2 2.58
74 1.2 3.49
24 0.6 2.23
66 2.0 2.27
55 1.9 6.0
103 3.9 10.0
15 0.3 0.7
114 1.7 1.5
36 1.0 1.4
102 2.9 4.3
35 1.1 1.9
130 3.8 5.9
26 1.6 3.4
74 2.4 7.3
44 4.3 4.4
88 4.9 8.3
40 1.7 3.9
97 4.1 6.0
34 1.4 1.8
85 3.5 3.3
32 1.2 2.1
89 3.2 2.9
61 2.8 —
72 2.7 —
33 0.7 2.6
85 3.3 6.6
5 0.4 0.8
93 4.2 3.5
23 1.4 3.9
41 3.0 5.1
38 0.8 3.9
96 3.9 9.3
14 0.9 1.7
81 4.1 4.9
33 1.4 2.8
15 1.0 1.5
90 3.4 5.6
20 0.8 2.5
Hct
Serum
Retic TRPCr Epo Fe TIBC TS Ferr
Patient % mg/dl mU/mi pg/d1 p.g/di % ng/ml PIT ETU % ig/m1
20.3
1.7
18.5
2.2
12.7 17 219 250 92 3586 0.72
222 243 94 — 1.02
14.8 27 100 285 36 818 0.46
94 284 32 — 0.72
7.9 20 219 271 81 2625 0.88
150 236 63 — 0.98
8.6 27 39 271 15 1059 0.53
91 323 29 — 1.13
23 144 269 56 2022 0.65
5 90 14 37 1315 0.19
139 272 55 0.96
61 40 30 0.17
11.0
3.3
10.1
9.6
11.9
13.5
16.3
12.3
2.7
41 1.4 3.7
14 0.4 1.4
75 2.4 4.9
26 0.3 2.1
20.5
2.5
18.6
1.8
0.35
0.67
0.36
0.73
0.44
0.64
0.60
0.83
0.65
0.89
15 U/kg
8211
8212
8213
8214
Mean
SD
Mean
SD
50 U/kg
8216
8217
8218
8219
8220
Mean
SD
Mean
SD
150 U/kg
8221
8222
8223
8824
8225
8111
8116
8117
8119
8123
8125
8126
8128
8129
8132
Mean
SD
Mean
SD
890 0.48
818 0.14
0.75
0.11
22 0.7 2.96
9 0.3 0.73
67 2.3 3.89
5 0.9 1.05
25 143 269 57
16 71 53 33
80 261 32
26 45 13
11.9 22 63 257
46 259
14.6 17 229 227
227 241
9.9 13 228 296
112 313
12.7 32 145 194
121 207
17.9 13 107 204
52 213
16.1 16 48 231
54 204
8.7 26 99 308
84 279
8.8 16 84 177
49 175
12.0 18 85 327
72 337
13.8 31 46 249
58 278
13.2 13 78 262
47 298
14.4 9 161 226
82 220
12.8 7 59 273
49 265
9.5 10 45 358
49 256
15.8 8 223 238
107 240
12.8
2.8
25 459
18 —
100 2863
94 —
77 900
36 —
75 2616
59 —
52 1482
25 —
21 384
26 163
32 174
30 73
47 1090
28 786
26 436
21 264
18 315
21 155
30 170
16 56
71 428
37 269
22 142
18 81
12 16
19 325
94 1436
45 1368
0.60
0.89
0.58
1.67
0.78
1.11
0.65
1.52
0.47
0.73
0.48
0.86
0.55
0.99
0.52
0.84
0.45
0.85
0.59
0.70
0.46
0.75
0.37
1.01
0.33
0.44
0.39
0.85
0.56
0.98
20.4
3.4
21.7
3.7
Abbreviations are: (h), hemochromatosis; Hct, hematocrit; Cr, serum creatinine; Epo, serum erythropoietin; Fe, serum iron; TS, transferrin
saturation; TIBC, total iron binding capacity; Ferr, serum ferritin; PIT, plasma iron turnover, mg/dl whole blood/day; ETU, erythron transfernn
uptake, mol iron/liter whole blood/day; Retic, reticulocytes, corrected; TRP, transferrin receptor protein.
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Recombinant human erythropoietin, U/kg
hemochromatosis, previously diagnosed by liver biopsy, who
had been undergoing periodic phlebotomy. Their baseline
erythropoiesis (ETU and plasma TRP levels) and serum Epo
levels were similar to the normal subjects, but the ETU
response to epoetin by the hemochromatosis subjects was
significantly greater than in the other normal subjects at the
dose of 150 U/kg. We have no good explanation for this
dichotomy in erythroid response. It is conceivable that the
precursor erythroid pool was expanded due to frequent phle-
botomy, but we purposely waited at least two weeks after a
phlebotomy before undertaking our study to be sure that
baseline erythropoiesis was normal. Although the percent of
reticulocytes was increased at baseline, the normal serum Epo
levels, ETU and TRP indicated that the hemochromatosis
patients had normal baseline erythropoiesis.
In a manner similar to our experimental animal studies [13],
we restudied three CRF patients after their renal and hema-
tological status returned to normal following successful kidney
transplantation. The doses of epoetin the patients received
when uremic were repeated when they were no longer anemic
or uremic. In all instances, the erythroid responses to exoge-
nous epoetin were similar in the normal or uremic states and
also similar to the other normal subjects, further supporting the
conclusion that the uremic state is not associated with clinically
significant inhibitors of erythropoiesis and also making it un-
likely that post-transplantation immunosuppression interfered
with the response to epoetin.
Experience with epoetin therapy in the anemia of CRF
supports the conclusion that uremia does not inhibit erythro-
poiesis. The response to epoetin in advancing renal failure is
similar to the response in well dialyzed patients [23]. The
25 Fig. 1. Erythropoietic response, as measured
by ferrokinetics (the erythron transferrin
uptake expressed as j.unol of iron per liter of
whole blood per day), following graded doses
of epoelin. These doses were given
intravenously every other day for 4 days.
Values are expressed as means standard
deviation (SD). Symbols are: CRF (A A);
normal subjects (O----O); Hemochromatosis(.
epoetin dosage required in CRF, although quite variable, is still
generally less than required for other Epo-responsive anemias
associated with normal renal function [59—61]. Although epoetin
administration often leads to serum Epo levels >100 mU/mi
[62—64], we do not believe that putative erythroid inhibitors
were simply overwhelmed by the epoetin doses in our study,
since the erythroid response was identical in all study groups,
including at low Epo doses.
There remains a dichotomy between the measurements of
baseline erythropoiesis and serum Epo levels when the CRF
patients are compared to normal subjects, raising the question
as to why there should be subnormal erythropoiesis in CRF
when serum Epo levels are "normal"? It is unlikely that the
serum Epo levels include biologically inactive hormone and are
falsely elevated due to the presence of immunoreactive frag-
ments of Epo [65, 66]. It is not known whether Epo receptor
physiology is different in uremia, which might explain this
dichotomy. Although serum Epo levels are within the
"normal" range in CRF, relative Epo deficiency exists because
the diseased kidney is unable to increase Epo production to
compensate for the shortened red cell survival and blood losses
(if present). Secondary factors that may contribute to the
anemia in CRF include iron deficiency, osteitis fibrosa of
hyperparathyroidism, severe aluminum excess, drug or im-
proper dialyzate induced hemolysis, and folate depletion [1].
These factors were excluded in our patients [15, 19].
In conclusion, we found no difference between normal and
CRF subjects in their response to recombinant human Epo as
reflected by acute changes in corrected reticulocyte count,
ETU and plasma levels of TRP, suggesting that the anemia of
CRF is primarily a hormone deficiency state.
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Fig. 2. Erythropoietic response, as measured
by the corrected reticulocyte count, following
graded doses of epoetin. Values are expressed
as means SD. Symbols are: CRF (A A);
normal subjects (including hemochromatosis
patients) (O----O).
Fig. 3. Erythropoietic response, as measured
by plasma levels of transferrin receptor
protein, following graded doses of epoetin.
Values are expressed as means SD.
Symbols are: CRF (A— A); normal subjects
(including hemochromatosis patients) (O----O).
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Table 3. Response to epoetin before and after kidney transplantation
Patient
Epo dose
U/kg
Hct
%
Serum
PIT ETU
Retic
%
TRP
j.g/m1
Cr
mgldl
Epo
mU/mi
Fe
pJdl
TIBC
g/dl
TS
%
Ferr
ng/mi
8216
1702
8225
50
50
100
100
150
150
18.0
18.4
38.6
39,2
29.7
29.0
40.0
38.8
23.0
20.2
38.8
35.8
10.1
1.7
9.8
1.4
17.9
1.2
48
20
9
28
13
14
147
77
84
41
90
71
75
65
107
52
62
40
289
312
297
294
248
221
238
220
204
213
286
285
52
25
28
5
36
32
32
30
52
25
22
14
885
—
392
171
282
201
161
97
1282
—
336
230
0.35
0.67
0.53
0.59
0.40
1.01
0.59
0.98
0.47
0.73
0.64
0.97
7
60
44
78
24
100
50
101
25
74
64
121
0.6
3.0
1.4
3.0
1.8
3.5
2.6
4.7
1.6
2.4
1.7
3.7
2.5
4.4
4.0
5.5
3.0
4.1
4.8
6.2
3.4
7.3
5.9
10.2
Abbreviations are: Hct, hematocrit; Cr, serum creatinine; Epo, serum erythropoietin; Fe, serum iron; TS, transferrin saturation; TIBC, total iron
binding capacity; Ferr, serum ferritin; PIT, plasma iron turnover, mg/dl whole blood/day; ETU, erythron transferrin uptake, jmo1 iron/liter whole
blood/day; Retic, reticulocytes, corrected; TRP, transferrin receptor protein.
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Fig. 4. Erythropoietic response to epoetin in
three patients with CRF before and after
successful kidney transplantation. Patients 1,
2 and 3, correspond to patients 8225, 1702 and
8216, respectively, in Table. Epoetin doses
were 150 U/kg (patient 1), 100 U/kg (patient 2)
and 50 U/kg (patient 3). Erythropoiesis was
monitored by the ETU, corrected reticulocyte
count and plasma TRP levels, before and after
4 doses of epoetin given intravenously every
other day for 4 doses. Symbols are: CRF
(A —A); transplantation (O----O).
References
I. ESCHBACH JW, ADAMSON JW: Anemia of end-stage renal disease
(ESRD). (Editorial Review) Kidney mt 28:1—5, 1985
2. ESCHBACH JW: The anemia of chronic renal failure: Pathophysiol-
ogy and the effects of recombinant erythropoietin. Kidney mt
35:134—148, 1989
3. JACOBSON LO, GOLDWASSER E, FRIEND W, PLZAK L: Role of the
kidney in erythropoiesis. Nature 179:633—634, 1957
4. NAETS JP, HUESE AF: Measurement of erythropoietic stimulating
factor in anemic patients with or without renal disease. J Lab Clin
Med 60:365—374, 1962
5. BROWN R: Plasma erythropoietin in chronic uraemia. Brit Med J
2:1036—1038, 1965
6. MARKSON JL, RENNIE JB: The anemia of chronic renal insuffi-
ciency. Scot Med J 1:320—322, 1956
7. FISHER JW: Mechanism of the anemia of chronic renal failure.
(Editorial Review) Nephron 25:106—111, 1980
Eschbach et a!: Erythropoietin in normal and uremic subjects 415
8. WALLNER SF, VAUTRIN RM: Evidence that inhibition of eryth-
ropoiesis is important in the anemia of chronic renal failure. J Lab
Clin Med 97:170—178, 1981
9. RADTKE HW, REGE AB, LAMARCHE MB, BARTOS D, CAMPBELL
RA, FISHER JW: Identification of spermine as an inhibitor of
erythropoiesis in patients with chronic renal failure. J C/in invest
67:1623—1629, 1980
10. VAN DYKE D, KEIGHLEY G, LAWRENCE J: Decreased responsive-
ness to erythropoietin in a patient with anemia secondary to chronic
uremia. (abstract) Blood 22:838, 1963
11. ESSERS U, MULLER W, HEINTZ R: Effect of erythropoietin in
normal men and in patients with renal insufficiency. Proc Eur Dial
Transplant Assoc 11:398—402, 1974
12. ESCHBACH JW, ADAMSON JW, DENNIS MB: Physiologic studies in
normal and uremic sheep. I. The experimental model. Kidney mt
18:725—731, 1980
13. ESCHBACH JW, MLADENOVIC J, GARCIA iF, WAHL PW, ADAMSON
JW: The anemia of chronic renal failure in sheep: The response to
erythropoietin-rich plasma in vivo. J Clin invest 74:434-441, 1984
14. WINEARLS CG, OLIVER DO, PIPPARD MJ, REID C, DOWNING MR,
C0TE5 PM: Effect of human erythropoietin derived from recombi-
nant DNA on the anaemia of patients maintained by chronic
haemodialysis. Lancet 11:1175—1178, 1986
15. ESCHBACH J, EGRIE J, DOWNING M, BROWNE JK, ADAMSON JW
Correction of anemia of end-stage renal disease with recombinant
human erythropoietin. N Engl J Med 316:73—78, 1987
16. BOMMER J, ALEXIOU C, MULLER-BUHL U, EIFERT J, RITZ E:
Recombinant human erythropoietin therapy in haemodialysis pa-
tients—dose determination and clinical experience. Nephrol Dial
Transplant 2:238—242, 1987
17. CASATI S, PASSERINI F, CAMPISE M, GRAZIANI G, CESANA B,
MERISIC M, PONTICELLI C: Benefits and risks of protracted treat-
ment with human recombinant erythropoietin in patients having
haemodialysis. Brit MedJ 295:1017—1020, 1987
18. AKIZAWA T, KOSHIKAWA S, TAKAKU F, URABE A, AKIYAMA N,
MIMURA N, OTSUBO 0, NIHEI H, SUGUKI Y, KAWAGUCHI Y, OTA
K, KUBO K, MARUMO F, MAEDA T: Clinical effect of recombinant
human erythropoietin on anemia associated with chronic renal
failure. A multi-institutional study in Japan. mt J Artf Organs
11:343—350, 1988
19. ESCHBACH JW, ABDULHADI MH, BROWNE JK, DELANO MD,
DOWNING M, EGRIE JC, EVANS RW, FRIEDMAN EA, GRABER SE,
HALEY R, KORBET S, KRANTZ SB, LUNDIN P, NissENsoN AR,
OGDEN DA, PAGANINI EP, RADER B, RUTSKY EA, STIVELMAN J,
STONE WJ, TESCHAN P. VAN STONE JC, VAN WYCK DB, ZUCK-
ERMAN K, ADAMSON JW: Results of a phase III multicenter clinical
trial with recombinant human erythropoietin in anemic patients
with end-stage renal disease. Ann Intern Med 1111:992—1000, 1989
20. SOBOTA JT: Recombinant human erythropoietin in patients with
anemia due to end-stage renal disease. Contrib Nephrol 76:166—178,
1989
21. STONE WJ, GRABER SE, KRANTZ SB, DESSYPRIS EN, O'NEIL VL,
OLSEN NJ, PINCUS TP: Treatment of the anemia of predialysis
patients with recombinant human erythropoietin: A randomized,
placebo-controlled trial. Am J Med Sci 296(3): 171—179, 1988
22. LIM VS, DEGOWIN RL, ZAVALA D, KIRCHNER PT, ABELS R,
PERRY P, FANGMAN J: Recombinant human erythropoietin in
pre-dialysis patients. A double-blind placebo-controlled trial. Ann
mt Med 110:108—114, 1989
23. ESCHBACH JW, KELLY MR, HALEY NR, ABELS RI, ADAMSON JW
Correction of anemia in progressive renal failure with recombinant
human erythropoietin. N Eng/ J Med 321:158—163, 1989
24, KLEINMAN KS, SCHWEITZER SU, PERDUE ST, BLEIFER KH,
ABEL5 RI: The use of recombinant human erythropoietin in the
correction of anemia in predialysis patients and its effect on renal
function: A double-blind, placebo-controlled trial. Am J Kidney Dis
14:486—495, 1989
25. TEEHAN BP, SIGLER MH, BROWN JM, BENZ RL, GILGORE GS,
SCHLEIFER CR, MORGAN CM, GABUZDA TG, KELLY JJ, FIGUEROA
WG, PETERSON DD: Hematologic and physiologic studies during
correction of anemia with recombinant human erythropoietin in
predialysis patients. Transplant Proc 21:63—66, 1989
26. ESCHBACH JW: Erythropoietin 1991—an overview. Am J Kidney
Dis 18(4), Suppl 1:3—9, 1991
27. EGRIE JC, C0TE5 PM, LANE J, GAINES DAS RE, TAM RC:
Development of radioimmunoassays for human erythropoietin us-
ing recombinant erythropoietin as tracer and immunogen. JImmu-
no! Meth 99:235—241, 1987
28. CooK JD, MARSAGLIA G, ESCHBACH JW, FUNK DD, FINCH CA:
Ferrokinetics: A biologic model for plasma iron exchange in man. J
Clin Invest 49:197—205, 1970
29. CAZZ0LA M, POOTRAKUL P, HUEBERS HA, ENG M, ESCHBACH
JW, FINCH CA: Erythroid marrow function in anemic man. Blood
1:296—301, 1987
30. HUEBERSHA, BEGUINY, POOTRAKUL P, EINSPI-IAR D, FINCH CA:
Intact transferrin receptors in human plasma and their relation to
erythropoiesis. Blood 75:102—107, 1990
31. SwINsCow TDV: Statistics at Square One. London, British Med-
ical Association, 1989
32. HARKER LA, SLICHTER Si: The bleeding time as a screening test
for evaluation of platelet function. N Engl J Med 287:155—159, 1972
33. Lvo M, MARCHESI D, REMUZZI G, GOTTI E, MECCA G, DEGA-
ETANO F: Uraemic bleeding. Role of anaemia and beneficial effect
of red cell transfusions. Lancet 11:1013—1015, 1982
34. Moi. M, VIZz0TT0 L, CATTANEO M, MANNUCCI PM, CASATI 5,
PONTICELLI C: Improvement in the haemostatic defect of uraemia
after treatment with recombinant human erythropoietin. Lancet
11:1227—1229, 1987
35. VAN GEET C, HAUGLUSTAINE D, VERRESEN L, VANRUSSELT M,
VERMYLEN J: Haemostatic effects of recombinant human erythro-
poietin in chronic haemodialysis patients. Thromb Haemost 61:
117—121, 1989
36. GORDGE, MP, LEAKER B, PATEL A, OVIASU E, CAMERON iS,
NEILD GH: Recombinant human erythropoietin shortens the
uraemic bleeding time without causing intravascular haemostatic
activation. Thromb Res 57:171—182, 1990
37. SCHWARTZ AB, KELCH B, TERZIAN L, PRIOR J, KIM KE, PEQUI-
NOT E, KAHN SB: One year of rHuEPO therapy prolongs RBC
survival and may stabilize RBC membranes despite natural pro-
gression or chronic renal failure to uremia and need for dialysis.
ASAIO Trans 36:M691, 1990
38. ADAMSON JW, EGRIE JC, HALEY NR, SCHNEIDER G, ESCHBACH
JW: Why do some hemodialysis patients (HDP) need large doses or
recombinant erythropoietin (rHuEpo)? (abstract) Kidney mt 37:
235, 1990
39. CARO J, BROWN 5, MILLER 0, MURRAY T, ERSLEV AJ: Erythro-
poietin levels in uremic nephric and anephric patients. J Lab Clin
Med 93:449—457, 1979
40. GARCIA, JF, SHERWOOD J, GOLDWASSER E: Radioimmunoassay of
erythropoietin. Blood Cell 5:405—419, 1979
41. MCGONIGLE RJS, WALLIN JD, SHADDUCK RK, FISHER iW: Eryth-
ropoietin deficiency and inhibition of erythropoiesis in renal insuf-
ficiency. Kidney mt 25:437—444, 1984
42. NAETS iP, GARCIA iF, TOUSAAINT CH, BUSET M, WAKS D:
Radioimmunoassay of erythropoietin in chronic uraemia or
anephric patients. Scand J Haematol 37:390—394, 1986
43. KUSHNERDS, BECKMAN B, FISHER JW: Do polyamines play a role
in the pathogenesis of the anemia of end-stage renal disease?
Kidney mt 36:171—174, 1989
44. KUSHNER D, BECKMAN B, NGUYEN L, CHEN 5, DELA SANTINA C,
HUSSERL F, RICE J, FISHER iW: Polyamines in the anemia of
end-stage renal disease. Kidney mt 39:725—732, 1991
45. ORTEGA JA, MALEKZADEH MH, DUKES PP. MA A, PENNISIAV,
FINE RN, SHORE NA: Exceptionally high serum erythropoietin
activity in an anephric patient with severe anemia. Am J Hematol
2:299—306, 1977
46. SHERWOOD JB, CHANG H, MITTMAN N, LONGNECKER R, GOLD-
WASSER E, NAGEL RL: Erythropoietin titers in sickle cell disease
and chronic renal failure. (abstract) Blood (Suppl. 1) 58:49, 1981
47. MCGONIGLE RJS, HUSSERL F, WALLIN iD, FISHER iW: Hemodi-
alysis and continuous ambulatory peritoneal dialysis effects on
erythropoiesis in renal failure. Kidney mt 25:430—436, 1984
48. ESCHBACH JW, ADAMSON JW, COOK JD: Disorders of red blood
cell production in uremia. Arch intern Med 126:812—815, 1970
49. ZAPPACOSTA AR, CARO J, ERLEV A: Normalization of hematocrit
416 Eschbach et a!: Erythropoietin in normal and uremic subjects
in patients with end-stage renal disease on continuous ambulatory
peritoneal dialysis. Am J Med 72:53—57, 1982
50. SEGAL GM, STUEVE T, ADAM5ON JW: Spermine and spermidine
are non-specific inhibitors of in vitro hematopoiesis. Kidney mt
31:72—76, 1987
51. DELWIcHE F, SEGAL GM, E5cHBAcH JW, ADAM5ON JW: Hema-
topoietic inhibitors in chronic renal failure. Lack of in vitro
specificity. Kidney mm 29:641—648, 1986
52. CARO J, HIcKEY J, ER5LEv AJ: Is spermine the uremic erythropoi-
etic inhibitor? (abstract) Clin Res 3 1:309, 1983
53. SEGAL GM, E5cHBACH JW, EGRIE JC, STUEVE T, ADAM5ON JW
The anemia of end-stage renal disease: Hematopoietic progenitor
cell response. Kidney mt 33:983—988, 1988
54. S.rro A, TAKAGI T, CHUNG TG, OHTA KAzul-uao: Serum levels
of polyamines in patients with chronic renal failure. Kidney mt
24:S234—237, 1083
55. Spit&cc BP, BENTLEY DP, C0LE5 GA: Anaemia of chronic renal
failure. Polyamines are not raised in uraemic serum. Nephron
38:65—66, 1984
56. CHARLES G, LUNDIN AP III, DELANO BG, BROWN C, FRIEDMAN
EA: Absence of anemia in maintenance hemodialysis. mt j Artjf
Organs 4:277—279, 1981
57. ZAROULIs CG, HOFFMAN BJ, KOURIDE5 IA: Serum concentrations
of erythropoietin measured by radioimmunoassay in hematologic
disorders and chronic renal failure, Am J Hematol 11:85—92, 1981
58. TAN CC, EcKARDT K, RATCLIFFE PJ: Organ distribution of eryth-
ropoietin messenger RNA in normal and uremic rats. Kidney mt
40:69—76, 1991
59. MEANS RT JR, OLSEN NF, KRANTZ SB, DEssvPRLs EN, GRABER
SE, STONE WJ, O'NEIL VL, PiNcus T: Treatment of the anemia of
rheumatoid arthritis with recombinant human erythropoietin: Clin-
ical and in vitro studies. Arth Rheu 32:638—642, 1989
60. FI5cHL M, GALPIN JE, LEVINE JD, GROOPMAN JE, HENRY DH,
KENNEDY P, MILES 5, ROBBINS W, STARRE-I-r B, ZALU5KY R,
ABELS RI, T5AI HC, RUDNIcK SA: Recombinant human erythro-
poietin for patients with AIDS treated with zidovudine. N Eng! J
Med 322:1488—1493, 1990
61. LUDWIG H, FRITZ E, KOTZMANN H, HOcKER P, GI5SLINGER H,
BARNA5 U: Erythropoietin treatment of anemia associated with
multiple myeloma. N EngI J Med 322:1693—1699, 1990
62. C0TE5 PM, PIPPARD MJ, REID CDL, WINEARLS CG, OLIVER DO,
RAY5TON JP: Characterization of the anaemia of chronic renal
failure and the mode of its correction by a preparation of human
erythropoietin (rHuEPO). An investigation of the pharmacokinetics
of intravenous erythropoietin and its effects on erythrokinetics.
Quart J Med 70:113—137, 1989
63. McMAHON FG, VARGAS R, RYAN M, JAIN AK, ABEL5 RI, PERRY
B, SMITH IL: Pharmacokinetics and effects of recombinant human
erythropoietin after intravenous and subcutaneous injections in
healthy volunteers. Blood 75:1718—1722, 1990
64. EGRIE JC, EScHBAcH JW, McGUIRE T, ADAMSON JW: Pharmaco-
kinetics of recombinant human erythropoietin (rHuEpo) adminis-
tered to hemodialysis (HD) patients. (abstract) Kidney mt 33:262,
1988
65. SHERWOOD JB, CARMIcHAEL LD, GOLDWAS5ER E: The heteroge-
neity of circulating human serum erythropoietin. Endocrinology
122:1472, 1988
66. LAPPIN TRJ, GOLDWASSER E, KUNG C: Erratum. Endocrinology
128:440, 1991
